US Patent 10059762 Anti-EGFR activatable antibodies
Patent 10059762 was granted and assigned to CytomX Therapeutics on August, 2018 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
April 28, 2016
Date of Patent
August 28, 2018
Patent Applicant
Patent Application Number
15140944
Patent Citations Received
•••
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 10059762 Anti-EGFR activatable antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
